Mirati Therapeutics (MRTX) Short Interest Ratio & Short Volume → The Gold Grab of the Century (From Colonial Metals) (Ad) Free MRTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability Mirati Therapeutics Short Interest DataCurrent Short Volume4,390,000 sharesPrevious Short Volume7,400,000 sharesChange Vs. Previous Month-40.68%Dollar Volume Sold Short$257.91 millionShort Interest Ratio / Days to Cover2.0Last Record DateDecember 31, 2023Outstanding Shares70,150,000 sharesPercentage of Shares Shorted6.26%Today's Trading Volume0 sharesAverage Trading Volume2,758,857 sharesToday's Volume Vs. Average0% Short Selling Mirati Therapeutics ? Sign up to receive the latest short interest report for Mirati Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatMRTX Short Interest Over TimeMRTX Days to Cover Over TimeMRTX Percentage of Float Shorted Over Time Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... Mirati Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 12/31/20234,390,000 shares $257.91 million -40.7%N/A2 $58.75 12/15/20237,400,000 shares $427.65 million +56.1%N/A3.3 $57.79 11/30/20234,740,000 shares $269.00 million -22.2%N/A2.1 $56.75 11/15/20236,090,000 shares $342.32 million +31.8%N/A2.7 $56.21 10/31/20234,620,000 shares $256.55 million -0.9%N/A2 $55.53 10/15/20234,660,000 shares $260.73 million -45.8%N/A2.1 $55.95 Get the Latest News and Ratings for MRTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 9/30/20238,590,000 shares $374.18 million -5.1%N/A4.4 $43.56 9/15/20239,050,000 shares $299.10 million -4.3%N/A7 $33.05 8/31/20239,460,000 shares $351.91 million -1.8%N/A8 $37.20 8/15/20239,630,000 shares $382.60 million +19.6%N/A7.7 $39.73 7/31/20238,050,000 shares $243.67 million -7.9%N/A6.9 $30.27 7/15/20238,740,000 shares $309.66 million +1.6%N/A8.5 $35.43 6/30/20238,600,000 shares $310.72 million +6.6%N/A8.3 $36.13 6/15/20238,070,000 shares $314.49 million +13.5%N/A7.7 $38.97 5/31/20237,110,000 shares $264.21 million +5.2%N/A6.8 $37.16 5/15/20236,760,000 shares $334.21 million -14.8%N/A6.9 $49.44 4/30/20237,930,000 shares $351.38 million -13.6%N/A7.9 $44.31 4/15/20239,180,000 shares $360.32 million -0.9%N/A8.6 $39.25 3/31/20239,260,000 shares $344.29 million +7.7%N/A8.3 $37.18 3/15/20238,600,000 shares $371.26 million -2.4%N/A6.8 $43.17 2/28/20238,810,000 shares $403.85 million -3.9%N/A5 $45.84 2/15/20239,170,000 shares $446.67 million -3.9%N/A4.9 $48.71 1/31/20239,540,000 shares $509.53 million -10.3%N/A4.9 $53.41 1/15/202310,630,000 shares $458.05 million +1.0%N/A5.7 $43.09 12/30/202210,530,000 shares $477.11 million +6.6%N/A5.9 $45.31 12/15/20229,880,000 shares $420.30 million +30.0%N/A5.9 $42.54 11/30/20227,600,000 shares $694.49 million -5.9%N/A5.8 $91.38 11/15/20228,080,000 shares $585.80 million +4.5%N/A8.4 $72.50 10/31/20227,730,000 shares $520.38 million -2.3%N/A10 $67.32 10/15/20227,910,000 shares $528.78 million +2.5%N/A9.4 $66.85 9/30/20227,720,000 shares $539.16 million -3.4%N/A8.4 $69.84 9/15/20227,990,000 shares $659.10 million +7.3%N/A8.1 $82.49 8/31/20227,450,000 shares $603.67 million -1.6%N/A6.7 $81.03 8/15/20227,570,000 shares $653.44 million +8.5%N/A4.8 $86.32 7/31/20226,980,000 shares $449.51 million -13.3%13.7%4.3 $64.40 7/15/20228,050,000 shares $483.16 million -2.2%24.0%5.2 $60.02 6/30/20228,230,000 shares $552.48 million +46.7%24.5%5.6 $67.13 6/15/20225,610,000 shares $302.66 million +19.1%16.7%4 $53.95 5/31/20224,710,000 shares $184.44 million -9.6%9.2%3.9 $39.16 5/15/20225,210,000 shares $296.14 million +24.1%10.2%7.1 $56.84Elon’s New A.I. Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. MRTX Short Interest - Frequently Asked Questions What is Mirati Therapeutics' current short interest? Short interest is the volume of Mirati Therapeutics shares that have been sold short but have not yet been covered or closed out. As of December 31st, investors have sold 4,390,000 shares of MRTX short. Learn More on Mirati Therapeutics' current short interest. What is a good short interest ratio for Mirati Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MRTX shares currently have a short interest ratio of 2.0. Learn More on Mirati Therapeutics's short interest ratio. Which institutional investors are shorting Mirati Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Mirati Therapeutics: Equitec Proprietary Markets LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Mirati Therapeutics' short interest increasing or decreasing? Mirati Therapeutics saw a decline in short interest in December. As of December 31st, there was short interest totaling 4,390,000 shares, a decline of 40.7% from the previous total of 7,400,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Mirati Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Mirati Therapeutics: Alkermes plc (7.99%), Perrigo Company plc (2.88%), Alpine Immune Sciences, Inc. (7.23%), Nuvalent, Inc. (20.97%), Madrigal Pharmaceuticals, Inc. (17.14%), BridgeBio Pharma, Inc. (10.86%), CymaBay Therapeutics, Inc. (5.10%), Ultragenyx Pharmaceutical Inc. (5.32%), Insmed Incorporated (6.33%), Prestige Consumer Healthcare Inc. (3.72%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: General Motors ($4.15 billion), T-Mobile US, Inc. ($3.92 billion), TC Energy Co. ($3.66 billion), Charter Communications, Inc. ($3.35 billion), Coinbase Global, Inc. ($3.32 billion), Occidental Petroleum Co. ($2.91 billion), Tractor Supply ($2.80 billion), Rivian Automotive, Inc. ($2.44 billion), Moderna, Inc. ($2.41 billion), and United Rentals, Inc. ($2.23 billion). View all of the most shorted stocks. What does it mean to sell short Mirati Therapeutics stock? Short selling MRTX is an investing strategy that aims to generate trading profit from Mirati Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Mirati Therapeutics? A short squeeze for Mirati Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of MRTX, which in turn drives the price of the stock up even further. How often is Mirati Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MRTX, twice per month. The most recent reporting period available is December, 31 2023. More Short Interest Resources from MarketBeat Related Companies: Alkermes Short Interest Data Perrigo Short Interest Data Alpine Immune Sciences Short Interest Data Nuvalent Short Interest Data Madrigal Pharmaceuticals Short Interest Data BridgeBio Pharma Short Interest Data CymaBay Therapeutics Short Interest Data Ultragenyx Pharmaceutical Short Interest Data Insmed Short Interest Data Prestige Consumer Healthcare Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MRTX) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press